DRUG DISCOVERY

BiomimX provides advanced models for paradigmatic pathologies where treatments are absent or limited by poor prediction of existing preclinical models.

The poor predictability of current in vitro models makes the finding of new efficient therapeutics slow and often difficult for many pathologies. BiomimX provides advanced models for paradigmatic pathologies where treatments are absent or limited by poor prediction of existing preclinical models. Osteoarthritis is a key example, having a high incidence in the population but no effective treatments available. BiomimX believes that our advanced models can better recapitulate disease mechanisms and ultimately provide effective tools for screening potential new targets and drugs before reaching clinical studies.

DRUG SAFETY

BiomimX's beating heart on a chip, behaves like a human heart tissue. uHeart holds the capacity to reliably detect drug cardiac adverse effects where existing 2D cell culture and animal testing models currently fail.

Amongst different causes (efficacy, pharmacokinetics, etc), failure of candidate drugs during clinical stages is sometimes due to adverse effects undetected in preclinical animal models. This has a major impact on the economic burden of drug development and on the related attrition rates. Cardiotoxicity is the main cause of drug attrition during clinical and post-approval stages. uHeart, BiomimX's beating heart on a chip, behaves like a human heart tissue. uHeart holds the capacity to reliably detect drug cardiac adverse effects where existing 2D cell culture and animal testing models currently fail.

In vitro precision organ models

Future developments of in vitro preclinical tools include envisioned personalized medicine approaches, where candidate compounds and therapies are screened on disease- and, ultimately, patient-specific models.

Future developments of in vitro preclinical tools include envisioned personalized medicine approaches, where candidate compounds and therapies are screened on disease- and, ultimately, patient-specific models. It is believed that accounting for differences between individuals will allow to precisely identifying more effective therapeutic strategies. BiomimX targets this revolutionary vision with the final aim to approach the aspiration of defining treatments tailored on each single patient.

BiomimX S.r.l.

Via Durando 38/A

20158 Milano (Italy)

T: (+39) 02 2399 3377

@: info@biomimix.com

Follow us on social networks